Trends in Life Expectancy of Cystic Fibrosis Patients in Moscow and their Connection with the Treatment Received: Retrospective Analysis for 1993–2013

Cystic fibrosis is multiple organ pathology that requires a complex treatment. Its standardization and pharmacoeconomic analysis are absolutely necessary. We performed a retrospective analysis of the trends in life expectancy of cystic fibrosis patients who lived in
Moscow in 1993, 1998, 2003, 2008, and 2013. It was found that the survival rate of these patients depended on the choice of drug therapy (pancreatic enzymes, dornase alfa, intravenous and inhaled antipseudomonal antibiotics), changes in diet, active dispensary observation at a specialized center for cystic fibrosis, and neonatal screening. We determined the cost of drug therapy per patient. From 1993 to 2013, the survival rate of patients who lived in Moscow increased by more than 20 years (from 16 to 39 years, respectively). The average cost of therapy increased more than 10 times (from USD 1.8 to 21.9 thousand, respectively).

1. Красовский С. А., Самойленко В. А., Амелина Е. Л. Муковисци доз: диагностика, клиника, основные принципы терапии. Пульмонология и аллергология. 2013; 1: 42–46.

2. Living longer with Cystic Fibrosis. D. Hubert, N. Simmonds (eds.). European Cystic Fibrosis Society. 2015. 143 p.

3. Davis P. B., Drumm M., Konstan M. V. Cystic Fibrosis. Am. J. Resp. Crit. Care Med. 1996; 154 (5): 1229–1256.

4. Krauth C., Jalilvand N., Welte T., Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. PharmacoEcon. 2003; 21 (14): 1001–1024.

5. Huota L., Durieub I., Bourdya S., Gannea C., Bellonc G., Colina C., Touzeta S. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J. Cyst. Fibrosis. 2008; 7 (5): 403–408.

6. Heimeshoff M., Hollmeyer H., Schreyogg J., Tiemann O., Staab D. Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. Pharmacoeconomics. 2012; 30 (9): 763–777.

7. vanGool K., Norman R., Delatycki M. B., Hall J., Massie J. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health. 2013; 16 (2): 345–355.

8. Васильева Ю. И., Каширская Н. Ю., Мизерницкий Ю. Л., Капранов Н. И., Дробижев М. Ю. Ретроспективный анализ клинико-функциональной и фармакоэкономической эффективности современной терапии муковисцидоза у детей. Пульмонология. 2006; Приложение по муковисцидозу: 72–77.

9. Красовский С. А., Черняк А. В., Амелина Е. Л., Никонова В. С., Воронкова А. Ю., Самойленко В. А., Науменко Ж. К., Каширская Н. Ю., Капранов Н. И., Шерман В. Д., Шабалова Л. А., Чистякова В. П., Симонова О. И., Семыкин С. Ю., Горинова Ю. В., Авакян Л. В., Пет ро ва П. Н., Кусова З. А., Усачёва М. В., Самсонова М. В., Черняев А. Л., Чучалин А. Г. Динамика выживаемости больных муковисцидозом в Москве и Московской области за периоды 1992–2001 и 2002–2011 гг. Пульмонология. 2012; 3: 79–86.

10. Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2013. Published September 2014. 92 p. URL: https://www.cff.org/2013_CFF_Annual_Data_Report_to_the_Center_Directors.pdf (Available: 28.08.2015).

11. The Canadian Cystic Fibrosis Registry 2013 Annual Report. Published January 2015. 35 p. URL: http://www.cysticfibrosis.ca/wpcontent/uploads/2015/02/Canadian-CF-Registry-2013-FINAL.pdf (Available: 28.08.2015)

12. Блистинова З. А., Лешкевич И. А., Прошин В. А., Капра нов Н. И., Каширская Н. Ю. Методические рекомендации № 18 «Медико-социальная помощь больным муковисцидозом в г. Москве». М. 2001. 12 с.

13. Dentice R., Elkins M. Timing of dornasealfa inhalation for cystic fibrosis. Cochr. Cystic Fibrosis and Genetic Disorders Group. Published Online 11 May 2011. DOI: 10.1002/14651858.CD007923.pub2.

14. Симонова О. И., Лукина О. Ф. Дорназа альфа в России: 15 лет спустя. Эффективность препарата в базисной терапии у детей с муковисцидозом. Вопросы современной педиатрии. 2012; 11 (2): 132–138.

15. Sawicki G. S., Signorovitch J. E., Zhang J., Latremouille-Viau D., von Wartburg M., Wu E. Q., Shi L. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr. Pulmonol. 2012; 47 (1): 44–52

16. Проект национального консенсуса «Муковисцидоз: определение, диагностические критерии, терапия». Раздел «Ингаляционная терапия» (печатается с сокращениями). Вопросы современной педиатрии. 2014; 13 (6): 89–95.

17. Fuchs H. J., Borowitz D. S., Christiansen D. H. Effect of aeroso lized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N. Engl. J. Med. 1994; 331 (10): 637–642.

18. Mainz J. G., Schiller I., Ritschel C., Mentzel H. J., Riethmuller J., Koitschev A., Schneider G., Beck J. F., Wiedemann B. Sinonasal inhalation of dornasealfa in CF: A double-blind placebocontrolled cross-over pilot trial. Auris Nasus Larynx. 2011; 38 (2): 220–227.

19. Lebecque P. The Prognosis of Cystic Fibrosis — A Clini cian's Perspective, Cystic Fibrosis — Renewed Hopes Through Research. D. Sriramulu (ed.). 2012. URL: http://www.intechopen.com/books/cystic-fibrosis-renewed-hopes-through-research/the-prognosis-ofcystic-fibrosis-a-clinician-s-perspective (Available: 20.07.2015).

20. Cohen-Cymberknoh M., Shoseyov D., Kerem E. Managing Cystic Fibrosis Strategies That Increase Life Expectancy and Improve Quality of Life. Concise Clinical Review. Am. J. Respir. Crit. Care Med. 2011; 183: 1463–1471.